



InDex signs license agreement for cobitolimod with Viatrix Japan

Investor call 1 June 2023

Jenny Sundqvist, CEO

Johan Giléus, Deputy, CEO & CFO

Forward looking statements

This presentation contains certain forward-looking statements reflecting the Company's current view of future events and financial and operational performance. Such forward looking statements are associated with both known and unknown risks and circumstances outside the Company's control. All statements in this presentation other than statements of historical or current facts or circumstances are forward-looking statements. Forward looking statements are made in several sections of the presentation and can be identified by the use of terms or expressions such as "may", "could", "should", "anticipated", "estimated", "expected", "likely", "forecasted", "plans to", "aims to", or conjugations of such terms or similar terms. The forward looking statements only apply as of the date of this presentation. The Company has no intent or obligation to publish updated forward looking statements or any other information contained in this presentation based on new information, future events, etc. other than required by applicable law, regulation or regulatory framework.



OUR MISSION is to significantly **improve the lives of patients** suffering from immunological disorders by providing effective and safe drugs for diseases with high unmet medical needs.

Cobitolimod is a potential novel treatment for moderate to severe ulcerative colitis

- Being evaluated in global phase III program CONCLUDE
 - Induction Study 1: ongoing
 - Induction Study 2: initiated upon positive results in Induction Study 1
 - Maintenance Study: ongoing
- 2022: Unique decision by Japanese regulatory authority (PMDA)
 - Accepted Japanese patients in Induction Study 2 without phase I study in Japan
- March 2023: Positive results in pharmacokinetic study in Sweden
 - Confirming low systemic uptake of cobitolimod



cobitolimod

InDex has signed license agreement with Viatrix Japan

- On May 31, 2023 InDex signed licence agreement with Viatrix Japan
- Register & commercialize cobitolimod in Japan for the treatment of ulcerative colitis



Viatrix - great partner to optimize value of cobitolimod in Japan

- US-based global pharmaceutical company
- Formed through merger of Mylan and Upjohn in 2020
- Listed on Nasdaq US
- > 37,000 employees globally in >165 countries
- Have marketed products in the GI therapeutic area
- Sees a high potential for cobitolimod for the Japanese market



Financial terms of the license agreement

- Upfront fee of USD 10 million
- Development and sales milestone payments of up to USD 40 million
- Up to double-digit percentage royalties
- Percentage royalty depends on the level of product net sales annually



Close collaboration with Viatrix for the development of cobitolimod in Japan

InDex will be responsible for and fund:

- Global phase III program CONCLUDE
 - including a cohort of Japanese patients in Induction Study 2
- PK study in Japanese patients prior to filing

Viatrix will be responsible for and fund:

- Regulatory filing and commercialization in Japan
- Any additional Japanese-specific studies required in Japan





We believe this license agreement will maximize cobitolimod's sales potential in Japan and bring the benefits of this innovative therapy to patients!

QUESTIONS & ANSWERS